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Abstract
Background:  Rhesus  macaques  (RMs)  inoculated  with  live-attenuated  Rev-Independent  Nef¯  simian
immunodeficiency  virus  (Rev-Ind  Nef¯SIV)  as  adults  or  neonates  controlled  viremia  to  undetectable  levels  and
showed no signs of immunodeficiency over 6-8 years of follow-up. We tested the capacity of this live-attenuated virus
to protect RMs against pathogenic, heterologous SIVsmE660 challenges.
Methodology/Principal Findings: Three groups of four RM were inoculated with Rev-Ind Nef¯SIV and compared.
Group 1 was inoculated 8 years prior and again 15 months before low dose intrarectal challenges with SIVsmE660.
Group  2  animals  were  inoculated  with  Rev-Ind  Nef¯SIV  at  15  months  and  Group  3  at  2  weeks  prior  to  the
SIVsmE660 challenges, respectively. Group 4 served as unvaccinated controls. All RMs underwent repeated weekly
low-dose  intrarectal  challenges  with  SIVsmE660.  Surprisingly,  all  RMs  with  acute  live-attenuated  virus  infection
(Group 3) became superinfected with the challenge virus, in contrast to the two other vaccine groups (Groups 1 and
2) (P=0.006 for each) and controls (Group 4) (P=0.022). Gene expression analysis showed significant upregulation of
innate immune response-related chemokines and their receptors, most notably CCR5 in Group 3 animals during
acute infection with Rev-Ind Nef¯SIV.
Conclusions/Significance: We conclude that although Rev-Ind Nef¯SIV remained apathogenic, acute replication of
the vaccine strain was not protective but associated with increased acquisition of heterologous mucosal SIVsmE660
challenges.
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According  to  the  recent  UNAIDS  estimates
[www.unaids.org], approximately 40 million people are infected
with HIV worldwide. The only cost-effective strategy to curb this
epidemic will be an effective vaccine [1]. Among the various
strategies  tested  thus  far,  live-attenuated  simian
immunodeficiency  virus  (LASIV)  vaccination  was  tested  in
primate models and shown to provide good protection against
homologous  virus  challenges  [2-6]  but  less  so  against
heterologous virus challenges [7-11]. Parental SIVmac239 was
attenuated  using  various  approaches,  including  deletion  of
nonessential genes, mutations in virus sequences, or swapping
of important gene functions. The most popular LASIV studied in
the rhesus macaque (RM) model is SIVmac239, that lacks a
functional nef gene (SIVΔnef). Animals infected with SIVΔnef
maintained persistently low viral loads with stable CD4 counts
over  several  years  and  were  able  to  resist  challenges  with
high-dose  of  homologous  nef+  SIV  [2].  Further  virus
attenuations  [12-18],  as  in  the  SIVmac239Δ3  isolate  [16],
decreased  the  replicative  capacity  further,  but  also  reduced
levels of protection; when SIVmac239Δ3 was used to vaccinate
neonatal RMs, these animals were unable to control viremia
and  showed  signs  of  disease  progression,  including
development of AIDS [14]. Together, these findings led to the
threshold hypothesis [5,19]. Even RMs given SIVmac239Δ3 as
adults  developed  signs  of  immune  dysregulation  over  time:
more  than  half  showed  T-cell  depletion  after  6-8  years  of
follow-up  and  18%  developed  AIDS  [14,20].  These  data
indicated that deletion of nef in the SIVmac239 genome did not
fully  abrogate  pathogenicity  but  markedly  delayed  disease
progression.
Interestingly, pathogenicity of nef-deleted HIV has also been
reported  in  a  unique  cohort  of  long-term  non-progressors
(LTNP) of the Sydney Blood Bank, where people were infected
with nef-deleted HIV via transfusion from a single donor. These
recipients were initially healthy but some of them exhibited a
slow  increase  in  viral  loads,  which  ultimately  led  to  disease
progression and opportunistic infections [21,22].
We  have  reported  a  non-pathogenic  LASIVmac239
derivative,  in  which  Rev  and  the  Rev-Responsive  Element
(RRE)  were  replaced  by  the  constitutive  transport  element
(CTE) of simian retrovirus type D (SIV-D). The resulting Rev-
Independent  nef-deleted  SIV,  termed  Rev-Ind  Nef¯SIV,  is
critically dependent on CTE for viral RNA (vRNA) export into
the cytoplasm for its replication, although the transplanted SIV-
D  CTE  significantly  slowed  the  export  and  resulted  in  lower
viral replication in vitro and in vivo [23-26]. RMs inoculated with
Rev-Ind Nef¯SIV showed low viral loads during acute infection
and exhibited long-lasting, persistent humoral and cellular SIV-
specific immune responses [26,27]. In addition, RMs infected
with  Rev-Ind  Nef¯SIV  as  adults  or  neonates  and  followed
prospectively for 6-8 years controlled this virus and exhibited
no signs of immune dysfunction or progression to AIDS [25-27].
Thus, Rev-Ind Nef¯SIV not only appeared to represent a live-
attenuated  SIV  strain  but  may  also  be  truly  non-pathogenic
since not even RMs infected as neonates showed signs of SIV
disease. Given this safety profile, we sought to test the efficacy
of Rev-Ind Nef¯SIV as a vaccine candidate against challenge
with a heterologous virus.
Several  studies  examined  the  need  for  LASIV-induced
protective responses to develop over time, with some studies
describing  time-dependent  elicitation  of  protective  responses
by  the  attenuated  virus  [6,9,10,28-30]  and  (reviewed  in  3,5).
However,  neither  very  short  nor  very  long  time  spans  -  >8
years  –  between  the  initial  vaccination  and  pathogenic  virus
challenge have been investigated. Here, we tested the effect of
different  time  intervals  between  infection  with  live-attenuated
Rev-Ind  Nef¯SIV  and  intrarectal  (i.r.)  repeat  low-dose
challenges with heterologous SIVsmE660.
Results
Immunization of RMs with Rev-Ind Nef¯SIV and immune
responses
A total of 8 RMs were infected as neonates (4 RMs) or adults
(4  RMs)  with  the  live  attenuated,  Rev-Ind  Nef¯SIV  and
monitored prospectively for approximately 8 years (Groups 1
and 5, Figure 1). After the initial acute viremia phase, plasma
vRNA loads were persistently below the threshold of the assay
[25,26].  No  signs  of  immune  dysfunction  or  AIDS  were
observed,  and  all  animals  showed  persistent  humoral  and
cellular SIV-specific immune responses, consistent with chronic
infection  [25,26].  Multicolor  flow  cytometric  analysis
demonstrated preservation of the central memory (CM) subset
of T cells [25,26]. In efforts to boost immune responses, we re-
inoculated these monkeys with a high-dose (1.6 x 104 TCID50)
of Rev-Ind Nef¯SIV i.v. at 15 months prior to the pathogenic
SIVsmE660 challenges (-15 mos). In parallel, we challenged 4
naïve control monkeys to ensure the infectivity of the vaccine
virus inoculum (Group 2 “vaccine 15 mos prior”). The latter 4
monkeys had peak vRNA loads of 104-105 copies/ml at week 2
post-inoculation (p.i.), but viral loads declined rapidly thereafter
and became undetectable. In contrast, none of the vaccinees in
Group 1 or 5 had measurable viremia upon re-inoculation. All
vaccinees in Group 2 seroconverted by week 9 post-inoculation
as measured by Western blot analysis; all vaccinees in Group
1  and  5  remained  seropositive  through  8  years  of  follow-up.
Cellular SIV-specific immune responses were detected in both
RM  groups  as  measured  by  ELISPOT  assay  for  interferon
(IFN)-γ-producing cells after stimulation with peptide pools for
SIV  Gag  [27].  Hematological  values,  including  absolute
numbers and percentage of CD3+CD4+cells, CD4+/CD8+ ratios,
the  percent  CD4+CD29+  memory  T  cells,  and  the  number  of
platelets remained stable in Group 1 and 5 vaccinees during
the  post-boost  period  as  well  as  in  Group  2  RMs  (data  not
shown).  No  differences  were  observed  in  the  frequencies  of
CM populations of CD4+ cells (CD28+CD95+) and CD8+ cells
(CD45RA-CCR7+)  as  measured  by  multicolor  flow  cytometric
analysis (data not shown).
Repeated low-dose and high dose SIVsmE660 i.r.
challenges
As  it  is  unlikely  that  any  AIDS  vaccine  recipient  will  be
exposed to an HIV variant exactly matching the immunogens,
vaccine  efficacy  needs  to  be  evaluated  using  heterologous
Increased SIV Acquisition
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e75556Figure 1.  Vaccination strategy with Rev-Ind Nef¯SIV and SIVsmE660 challenges.  RMs in Groups 1(low-dose challenge group)
5 and (high-dose only challenge group) had been vaccinated with Rev-Ind Nef¯SIV >8 yrs ago and boosted along with Group 2
monkeys; RMs in Group 2 were vaccinated with Rev-Ind Nef¯SIV 15 months prior to SIVsmE660 low-dose challenges, RMs in
Group 3 were vaccinated with Rev-Ind Nef¯SIV 2 weeks prior to SIVsmE660 low-dose challenges; Group 4 consisted of naïve RMs
that served as controls for SIVsmE660 challenges; Groups 6, served as control unvaccinated group was challenged with a high-
dose of SIVsmE660 only and Group 7 received only Rev-Ind Nef¯SIV and was followed for 2 weeks. Groups 1-4 received the
maximum of 17 weekly low-dose i.r. challenges with SIVsmE660 (300 TCID50 as measured by TZM-bl assay). RMs that did not
become systemically infected after the 17 low-dose challenges (boxed names) were rechallenged i.r. with a single high dose of
SIVsmE660 (990 TCID50) and became infected (rechallenged Group 1-2 and high-dose control Group 6). Blue indicates the live
attenuated vaccine strain (Rev-Ind Nef¯SIV). A fifth monkey (RMw-6) did not fulfill the criteria of “vaccine take” (transient low-dose
Rev-Ind Nef¯SIV infection with vRNA of 1080 copies/ml at 2 weeks post-vaccination, the expected time of peak vaccine virus
viremia);  therefore,  data  from  RWm-6  were  not  included  in  the  analysis.  Thin  red  arrows  stand  for  the  weekly  low-dose  i.r.
exposures to the challenge virus, heterologous SIVsmE660; the thick red arrows represent single high-dose i.r. challenges with
SIVsmE660.
doi: 10.1371/journal.pone.0075556.g001
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of  Rev-Ind  Nef¯SIV-vaccinated  RMs  with  multiple  low-dose
mucosal exposures of SIVsmE660 as outlined in Figure 1. The
overall sequence difference between these two strains ranges
from 8-26% at the amino acid level. The highest difference is in
Tat  (26%),  followed  by  Env  (15.1%),  Vpr  (12%),  Pol  (8.3%),
and Gag (8%) [10]. The pathogenic SIVsmE660 exposure of
the different vaccine groups occurred at different time intervals
after the initial vaccination and ranged from 8 years to 2 weeks.
Viral RNA (vRNA) load determination was complicated by a
need to differentiate the challenge virus (SIVsmE660) from the
live  attenuated  vaccine  strain  (Rev-Ind  Nef¯SIV).  Since  the
latter was based upon the molecular clone of SIVmac239, we
developed  a  set  of  primers  that  only  recognized  Rev-Ind
Nef¯SIV but not the challenge virus SIVsmE660 [32]. A second
assay based upon primers developed by Cline et al. [33], was
then used to measure total vRNA. The difference between the
two  assays  reflects  vRNA  loads  due  to  SIVsmE660
superinfection.
All vaccinated RMs (Groups 1, 2 and 3) and control Group 4
were  challenged  up  to  17  times  i.r.  with  weekly  low-dose
SIVsmE660. Animals that remained aviremic after these 17 low
doses  were  given  a  single  high  dose  of  SIVsmE660  (boxed
animal names in Figures 1, 2). Remarkably, all 4 RMs of Group
3 challenged with SIVsmE660 2 weeks after receiving the live
attenuated Rev-Ind Nef¯SIV (i.e., peak viremia of the vaccine
strain, Figure 2G, week 0) became superinfected after only 1 to
3  low-dose  SIVsmE660  challenges  (Figure  2H).  In  contrast,
some vaccinees of Groups 1 and 2 (Figure 2A-F) as well as
control  Group  4  remained  aviremic  (Figure  2J-L).  Statistical
analysis  of  this  low-dose  challenge  phase  revealed  the
following  for  the  time-to-first  viremia  (defined  as  vRNA  >104
copies/ml):  Group  3  vs.  Groups  1  or  2  (P=0.006  for  each
comparison  by  Log  rank  test,  two-sided);  Group  3  vs.  the
combined  Groups  1  +  2  (P<0.001).  During  the  low-dose
challenge  phase,  viremia  developed  in  3  out  of  5  Group  4
controls  (Figure  2J-L).  Time-to-first-viremia  was  significantly
shorter for Group 3 vaccinees compared to Group 4 controls
(P=0.022).  Clearly,  Group  3  vaccinees  with  acute  vaccine
strain  infection  had  the  highest  SIVsmE660  acquisition  rate
with the fastest time to viremia compared to all other groups.
The fact that not all naïve controls became viremic prompted
the  high-dose  SIVsmE660  rechallenge,  after  which  all  virus-
only  controls  (Group  4  RMs  with  boxed  names  and  a  new
control Group 6 of naïve monkeys, Figure 1) became viremic
(Figure 2P-R). In addition, the 2 RMs from Group 1 and 3 RMs
from Group 2 that remained uninfected after the multiple low-
dose  challenges  (Figure  2A-F)  as  well  as  Group  5  monkeys
inoculated with Rev-Ind Nef¯SIV at -8 years and -15 months
(Figure  1)  were  also  subjected  to  the  single  high-dose  i.r.
SIVsmE660  challenge.  After  the  high-dose  rechallenge,  all
RMs became superinfected with the challenge virus except for
vaccinee RSb-3 that remained completely protected (Group 5,
Figure 2M-N), outlining the limits of protection from acquisition
of a heterologous mucosal challenge afforded by our LASIV. In
addition, while all animals from Group 1 and 2 except RAn-8
controlled  viremia  after  resolution  of  the  initial  SIVsmE660
infection,  vaccinees  challenged  with  a  single  high  dose  of
SIVsmE660  exhibited  persistent  viremia,  albeit  at  lower  set
points  than  Group  5  control  animals  (Figure  2).  Peak  vRNA
loads due to SIVsmE660 superinfection were also affected by
immunization with Rev-Ind Nef¯SIV. Control RMs of Groups 4
and 5 had peak vRNA loads of 106-108 copies/ml. Peak vRNA
loads for SIVsmE660 did not differ between Groups 3 and 4.
Group 1 vaccinees had peak vRNA loads ranging from 104-105
copies/ml,  except  in  vaccinee  RJi-6  (Group  1,  Figure  2N),
where  several  blips  of  below  ~103  copies/ml  were  noted.  A
significant difference in challenge virus peak vRNA loads was
noted  for  the  comparison  of  vaccinees  exposed  to  the
pathogenic  SIVsmE660  during  the  chronic  phase  of  live-
attenuated Rev-Ind Nef¯SIV infection (Groups 1 + 2) with that
of  RMs  during  acute  Rev-Ind  Nef¯SIV  infection  (Group  3)
(P=0.016 by Wilcoxon rank-sum test, two-sided; Figure 2B and
E, versus H).
All  newly  infected  animals  and  controls  seroconverted  by
week 9 post-challenge as measured by Western blot analysis.
We  conclude  that  exposure  to  pathogenic  challenge  virus  at
week 2, the time of peak vaccine strain viremia, not only failed
to protect but may even have increased host susceptibility to
the  heterologous  pathogenic  virus  challenge  in  comparison
with controls. Furthermore, exposure to pathogenic challenge
during  acute  vaccine  virus  infection  also  led  to  significantly
higher  viral  set  points  and  continued  replication  of  both
challenge and vaccine strains compared to vaccinees given the
live-attenuated virus 15 months to 8 years earlier.
SIV-specific immune responses before and after low-
dose challenges
Next, we measured anti-SIV Gag IFN-γ ELISPOT responses
before and during the low-dose SIVsmE660 challenges (Figure
3).  Only  low-level  IFN-γ  ELISPOT  responses  were  observed
among  Groups  1,  2,  and  3  prior  to  the  repeated  low-dose
challenges. These responses did not differ significantly among
the vaccine groups (P=0.19; Figure 3A). However, during the
low-dose  challenges,  SIV  Gag-directed  IFN-γ  ELISPOT
responses increased among all three vaccine recipient groups
and differed from controls (P=0.03; Figure 3B), particularly in
Group  1,  even  though  the  difference  between  the  vaccine
groups  never  reached  significant  statistical  difference.  SIV
Gag-specific  IFN-γ  ELISPOT  responses  on  the  day  of  the
single  high-dose  SIVsmE660  rechallenge  seen  among  the
vaccinees of Groups 1 and 2 that had not developed persistent
challenge  virus  viremia  during  the  low-dose  SIVsmE660
challenge  phase  (boxed  RMs  in  Figures  1  and  2B,E)  had
increased  above  the  levels  seen  prior  to  the  low-dose
challenge virus exposures, suggesting some boosting by the
repeat exposure (Figure 3C). Of interest was the finding that
SIVgag  specific  responses  did  not  correlate  with  protection
despite  the  equivalent  levels  of  such  responses  between
animals from Groups 2 and 3 in particular.
Given  the  higher  acquisition  rate  observed  in  Group  3
animals that were exposed to the pathogenic challenge virus at
the time of peak vaccine virus viremia, we sought to test PBMC
for  evidence  of  T-cell  activation  by  staining  for  Ki67,  CD69,
HLA-DR,  and  CCR5  by  multicolor  flow  cytometry.  Although
staining for Ki67 on CD3+ cells was higher for Group 3 animals
Increased SIV Acquisition
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e75556Figure  2.    Plasma  vRNA  loads  after  low-dose  (A-B;  D-E;  G-H;  J-K)  or  high-dose  (M-N;  P-Q)  SIVsmE660
challenges.  Horizontal dashed lines in all panels represent the limit of detection of the RT-PCR assay (50 vRNA copies/ml) [32,33].
RMs in boxes were entered into the single high-dose challenge with SIVsmE660 (thick arrow) shown in M-N and P-Q. The panels in
(C, F, I, L, O, R) are mean vRNA loads of each group. Blue, indicates vRNA loads for the live attenuated vaccine strain (Rev-Ind
Nef¯SIV), purple indicates vRNA loads both vaccine + challenge virus, and the red line indicates challenge virus-specific vRNA
loads.
doi: 10.1371/journal.pone.0075556.g002
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Gag-specific,  IFN-γ-secreting  cells  were  measured  by
ELISPOT assay (A) before the low-dose SIVsmE660 challenge
phase, (B) during the low-dose challenge phase, or (C) after
the low-dose phase but before the high dose rechallenge with
SIVsmE660  and  (D)  T  cell  activation  was  measured  by
percentage of CD3+ Ki67+ cells.
doi: 10.1371/journal.pone.0075556.g003
compared to those of Groups 1+2 and 4, statistical significance
was  not  reached  (P=0.16)  (Figure  3D).  Furthermore,  in
consideration of the potential inflammation induced by Rev-Ind
Nef¯SIV in Group 3 monkeys, we also measured the relative
representation  of  total  CD4+  T  cells,  CD4+CD45RA-CCR5+,
CD45RA-CCR7+  memory  and  CD4+  CD28+  CD95+  central
memory cells before and 2 weeks after post-infection (Group
7).  As  shown  in  Figure  S1,  higher  percentages  of  these
populations  were  noted  at  2  weeks  post  Rev-Ind  Nef¯SIV
infection  relative  to  baseline  confirming  the  microarray  data.
However,  phenotypic  analysis  did  not  reach  statistical
significance, likely due to the small number of animals.
The potential influence of host restriction factors on
viral loads
The  animals  were  enrolled  and  grouped  years  before  the
influence  of  MHC  class  I  or  TRIM5α  alleles  on  viral  loads
became known. However, it is now generally recognized that
low-dose  SIVsmE660  challenges  may  be  influenced  by
TRIM5α  alleles  [7,34].  We  therefore  typed  all  vaccinees  and
controls  enrolled  in  this  study  for  their  MHC  Class  I  and
TRIM5α genotypes (Table 1; RMs in Group 6 are not included
in  this  discussion  since  they  did  not  undergo  SIVsmE660
challenge).  While  the  distribution  of  TRIM5a  alleles  was  not
perfectly equal among groups, it remains comparable with only
1  sensitive  genotype  in  Groups  2,  3  and  5  while  the  other
groups  comprised  a  blend  of  moderately  to  highly  restrictive
genotypes.  Of  note,  neither  TRIM5α  nor  the  MHC  B*008  or
B*017 appeared to greatly affect the susceptibility of infection
within any defined group except perhaps for Group 2 (Table 1).
Of note though, the low-dose control Group 5 comprised four
out of five “restrictive” genotypes, which may have lead to two
RMs  requiring  17  weekly  low-dose  SIVsmE660  challenges.
However, the other 2 animals possessing a restrictive genotype
as well as the fifth, with a moderate genotype, were infected
rapidly during the low dose challenge series, suggesting that
perhaps other yet to be defined factors played a role. Of note,
all  controls,  regardless  of  their  TRIM5α  or  MHC  genotype,
became  infected  after  the  single  high-dose  SIVsmE660
challenge.  Finally,  we  also  performed  statistical  analysis  by
combining  restrictive,  moderate,  susceptibility  to  infection  of
TRIM5α alleles of all the vaccinees vs. control RMs for virus
acquisition.  We  noted  that  vaccinees  and  control  RMs
experienced  comparable  acquisition  rates  over  the  first  4
challenges and after that, vaccinees showed slower acquisition
compared  to  controls  (P=0.045;  based  on  Mantel-Cox  test)
which is in agreement with recently published studies [35,36],
suggesting  that  TRIM5α  played  a  minor  role  at  best  in
acquisition of infection in this study.
Gene expression analysis of RMs 2 weeks after i.v.
vaccination with Rev-Ind Nef¯SIV (Group 7)
To  understand  the  potential  mechanism  that  led  to  the
increased susceptibility of RMs to challenge virus acquisition 2
weeks  after  the  inoculation  of  Rev-Ind  Nef¯SIV,  three  naïve
RMs  were  enrolled  for  PBMC  and  rectal  tissue  gene-
expression profiling before and after vaccination with Rev-Ind
Nef¯SIV (Group 7, Figure 1 and Table 1); these additional RMs
Increased SIV Acquisition
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e75556were vaccinated similar to Group 3 animals and monitored for
plasma vRNA loads (Figure 4A). At week 2, all three Group 7
RMs  were  euthanized,  and  PBMC  and  rectal  biopsies  were
collected  using  identical  procedures  pre-vaccination,  thus
allowing  us  to  compare  paired  samples  from  each  RM,  with
pre-vaccination samples as autologous controls for microarray
analysis  (Methods;  Figure  4B).  Unsupervised  analysis  using
PCA showed a tight grouping of PBMC samples, while rectal
tissues exhibited greater heterogeneity.
Supervised  analysis  identified  approximately  100  individual
genes that were differentially expressed in PBMC (Figure 4C)
when comparing pre- and post-vaccination samples but none in
rectal biopsies. We noted a clear upregulation of expression of
a  set  of  chemokine  and  chemokine  receptors,  most  notably
CCL3,  also  known  as  macrophage  inflammatory  protein-1α
(MIP-1α), and C-C chemokine receptor 5 (CCR5). We further
validated  the  increased  expression  of  CCR5  by  quantitative
qPCR (data not shown). Increased expression was seen also
for  several  genes  involved  in  different  cellular  processes,
including  cell  cycle,  signal  transduction  and  chromatin
remodeling (Figure 4C). In contrast, gut biopsies exhibited no
such  differences,  suggesting  that  relatively  few  changes
occurred in the gut during acute infection with Rev-Ind Nef¯SIV
or  that  tissue  sample  heterogeneity,  the  relatively  few
lymphocytes  residing  in  the  mucosal  tissues,  and  the  low
number  of  RMs  available  did  not  permit  observation  of
significant differences.
Table 1. TRIM5α and MHC Genotypes.
RM # TRIM5α genotype Susceptibility to infection MHC genotypes # SIVsmE660 challenges
      A01 B08 B17 Low-dose High-dose
Group 1 (vaccine 8 yrs prior, followed by low-dose repeated challenge)
RJi-6 TFP/ Q moderate – – – 17 1
ROI-3 TFP/ TFP restrictive – – – 5 0
RQh-6 Q/ CYPA moderate – – – 17 1
RUu-3 TFP/ TFP restrictive – + – 4 0
Group 2 (vaccine 15 mos prior, followed by low-dose repeated challenges)
RAn-8 Q/ Q high – – – 6 0
RBm-8 TFP/ Q moderate + – – 17 1
RCa-9 Q/ CYPA moderate – – – 17 1
RQm8 Q/CYPA moderate + – – 17 1
Group 3 (vaccine 2 wks prior, followed by low-dose repeated challenges)
RBr-9 Q/CYPA moderate + – + 1 0
REd-10 TFP/ TFP restrictive + – – 1 0
RQy-9 Q/ CYPA moderate – – – 1 0
RZi-7 Q/TRIM Q high – – – 1 0
Group 4 (low-dose controls for low dose repeated challenges)
REf-7 TFP/ TFP restrictive + – – 17 1
REy-6 TFP/ TFP restrictive – – – 4 0
RFz-6 TFP/ TFP restrictive – – – 2 0
RHt-9 TFP/ TFP restrictive + – – 17 1
RMg-10 Q/CYPA moderate + – – 1 0
Group 5 (vaccine 8 yrs prior, followed by high-dose challenge)
N901 TFP/ TFP restrictive – – – NA 1
RKh-6 TFP/ Q moderate – – – NA 1
RPh-6 TFP/ TFP restrictive – – – NA 1
RSB3 TFP/ CYPA moderate – – – NA 1
Group 6 (high-dose controls for high dose challenge)
RBj-7 Q/ Q high – – – NA 1
RCn-7 TFP/TFP restrictive – – + NA 1
RDt-9 TFP/ TFP restrictive – – – NA 1
RIr-7 TFP/ CYPA moderate – – – NA 1
RYt-9 TFP/ TFP restrictive – + – NA 1
Group 7 (vaccine only for 2 wks)
RAm-5 TFP/ TFP restrictive + – + no no
RMh-9 TFP/ Q moderate + – – no no
RRu-7 TFP/ Q moderate – + – no no
doi: 10.1371/journal.pone.0075556.t001
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Analysis (IPA) showed that the top network genes regulated by
Rev-Ind  Nef¯SIV  include  functional  groups  responsible  for
hematopoiesis, cellular movement, and immune cell trafficking.
Several functionally linked genes were upregulated as shown
in Figure 5. Network analysis revealed that a set of upregulated
chemokines  and  chemokine  receptors  formed  clusters/cores
with  NF-ĸB  and  other  signaling  molecules  (Figure  5).
Collectively, these data indicate Rev-Ind Nef¯SIV vaccination
induced immune activation within 2 weeks of infection that was
clearly discernible in PBMC but not in rectal tissues. In turn,
immune activation caused by the live attenuated vaccine virus
may  have  increased  host  susceptibility  to  the  heterologous
SIVsmE660 during the low-dose challenges and facilitated its
dissemination.
Discussion
In the present study, we observed that 1) RMs vaccinated
with  Rev-Ind  Nef¯SIV  two  weeks  prior  to  the  onset  of
challenges with pathogenic SIVsmE660 were more susceptible
to  this  heterologous  virus  compared  to  monkeys  with  much
longer  time  intervals  between  live-virus  exposure  and
SIVsmE660 challenges; 2) microarray analysis suggested that
a  generalized  immune  activation  led  to  enhancement  of
chemokines and chemokine receptors, most notably CCL3 and
CCR5,  which  may  have  increased  host  susceptibility  to
superinfection  by  the  heterologous  SIVsmE660  during  acute
infection with the vaccine strain, Rev-Ind Nef¯SIV; and 3) while
Rev-Ind  Nef¯SIV  induced  some  level  of  protection,  this
protection  was  not  absolute,  as  most  vaccinated  animals
became superinfected after a high-dose SIVsmE660 challenge.
Figure 4.  vRNA load measurements, principal component analysis (PCA) and heatmap analysis.  (A) vRNA loads were
measured at 2 weeks after Rev-Ind Nef¯SIV vaccination (Group 7; 3 RMs) The RMs were subsequently euthanized to collect rectal
tissues and PBMC. (B) PCA was performed on log2 expression measures for autologous PBMC and rectal biopsy specimens
collected before and two weeks after inoculation with the live attenuated vaccine strain, Rev-Ind Nef¯SIV. Infected and naïve PBMC
samples were centered and grouped together, indicating that the samples were nearly homogenous. In contrast, we observed
heterogeneity in rectal tissues. (C) Hierarchical clustering of differentially expressed genes in PBMC. Supervised analysis identified
approximately  100  differentially  expressed  genes  between  PBMC  of  the  RMs  collected  before  and  after  vaccination  using  a
significance threshold of a false discovery rate) <5% and log2 fold-change >1 was analyzed using average-linkage hierarchical
clustering with a Pearson correlation coefficient distance metric. We noted a clear upregulation of expression of a set of chemokines
and chemokine receptors, most notably CCL3, and CCL5 (highlighted).
doi: 10.1371/journal.pone.0075556.g004
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mucosal  challenges  has  been  reported  to  be  influenced  by
TRIM5α  [37],  results  from  the  present  study  and  additional
SIVsmE660  mucosal  titration  studies  at  the  Yerkes  NPRC
suggest  a  moderate  influence  of  this  antiviral  factor  in
acquisition at best. In addition such influence was even less
prevalent with a higher dose mucosal challenge during which
all animals became infected. Furthermore, the levels of steady-
state  viremia  were  also  found  to  be  influenced  by  TRIM5α
alleles after infection with SIVsmE660 or the molecular clone
SIVsmE543-3 [38,39].
Significant levels of protection have been achieved against
primate lentivirus infection with live-attenuated SIV [2,3,40,41],
although  translation  of  such  strategy  to  humans  is
unacceptable  due  to  the  residual  pathogenic  potential  of
standard  nef-deleted  vaccine  viruses,  including  nef-deleted
HIV-1  [21,22],  and  recombination  between  vaccine  and
challenge  viruses  [10].  While  most  live-attenuated  SIV
approaches have inactivated the accessory genes nef and/or
vpr,  our  team  has  generated  a  unique  series  of  replication-
competent  isolates  lacking  Rev-RRE  transport  elements.
These  Rev-independent  SIV  strains  have  a  critical  need  for
RNA  transport  elements  from  other  sources  for  replication.
Unlike SIVΔNef or Δ3, this Rev-Ind Nef¯SIV has been shown
to be apathogenic even when neonatal RMs were inoculated
[27],  which  prompted  us  to  assess  the  efficacy  of  this  live
Figure 5.  Network pathway analysis.  Network pathway analyses were performed using the Ingenuity Pathway Analysis Network
tool. Node colors show the average gene expression levels of RMs vaccinated with Rev-Ind Nef¯SIV relative to the average before
vaccination  (red,  relative  increase  in  expression;  green,  relative  decrease  in  expression).  CCR5,  CCL3  and  other  signaling
molecules  were  upregulated  and  were  directly  and  indirectly  involved  with  other  immune  system  pathways.  The  numbers
underneath the nodes are 1) log2-fold change, and 2) FDR-adjusted P values.
doi: 10.1371/journal.pone.0075556.g005
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vaccination and challenge with a heterologous, pathogenic SIV.
To our surprise, exposure of RMs during the acute phase of
live-attenuated  Rev-Ind  Nef¯SIV  infection  to  the  pathogenic
SIVsmE660  given  as  repeated  low-dose  i.r.  challenges
significantly increased acquisition of the challenge virus. Earlier
studies  [41,42]  had  reported  a  need  for  maturation  of  the
protective responses induced by vaccination with nef-deleted
SIV, which was implied by the increased fraction of vaccinated
RMs that were protected from wild-type SIV rechallenge with
increasing time intervals between vaccination and pathogenic
SIV challenge. However, our data indicate for the first time an
enhancement of virus acquisition at a very early time point (~ 2
weeks) post vaccination, especially when comparing Groups 1
and  2  exposed  to  LASIV  15  or  more  months  before
SIVsmE660  challenge  with  Group  3  monkeys  (Figure  2),
leading  to  chronic  replication  of  both  the  attenuated  and
challenge virus in the latter group. Our microarray data suggest
that the mechanisms facilitating challenge virus acquisition may
be innate and non-specific, a concept that is supported by the
upregulation of chemokine and the chemokine receptor CCR5,
which  probably  increased  the  number  of  susceptible  target
cells  [43],  even  though  this  upregulation  on  potential  target
CD4+ T cells was not statistically significant according to the
phenotypic analyses in blood.
The mechanisms of protective immunity elicited by the live-
attenuated SIV vaccines remain somewhat unclear. Previous
studies reported that transient depletion of CD8+ cells during
chronic  infection  leads  to  a  significant  increase  of  transient
plasma vRNA levels in animals vaccinated with live-attenuated
SIV,  even  though  detection  of  SIV  specific  CD8+  T  cell
responses were low except in lymphoid organs [10,29,44-46].
However,  recent  developments  in  the  vaccine  protection
experiments suggest a role for other mechanisms in vivo such
as  ADCC,  which  is  mediated  by  CD8αα+  natural  killer  cells
[47,48]. Similar to other LASIV vaccinations, animals infected
with  Rev-Ind  Nef¯SIV  for  over  1  year  clearly  had  developed
various  levels  of  humoral  and  cell  mediated  responses,  yet
these response were generally modest compared in response
to wild type SIV [45] [41]. Therefore, monkeys that had been
inoculated  8  years  ago  were  boosted  at  -15  months  before
heterologous virus challenge, in an attempt to enhance and or
re-mobilize SIV specific responses. It is unclear whether such
measures resulted in any difference in protective mechanisms,
since there was no apparent difference between Group 1 and
Group  2  RMs,  relative  to  low  or  high  dose  heterologous
mucosal  challenge.  One  salient  outcome  of  these  studies
though, was the realization of the limits of limit of protection
afforded by LASIV in a model that used heterologous mucosal
challenge.  Superinfection  was  achieved,  especially  when
higher  inoculum  exposures  were  performed,  although  some
control of chronic viremia was still achieved in Groups 1 and 2
vaccinees  post  infection,  especially  for  those  RMs
superinfected by low dose challenges (Figure 2C, F and L).
We  have  identified  acute  infection  with  a  live  attenuated
vaccine  strain  as  a  cause  for  increased  acquisition  of
heterologous,  pathogenic  challenge  virus.  The  mechanism(s)
involved  upregulation  of  innate  immunity  associated  genes.
Acute  infection  with  other  organisms  could  result  in  similarly
increased  rates  of  lentivirus  acquisition,  which  has  been
demonstrated for herpes simplex virus type-2 (HSV-2) [49-52]
and parasites [53,54]. Modulation of HIV acquisition rates has
been reported during de novo HSV-2 infection in epidemiologic
studies  that  found  a  7-fold  increase  in  the  risk  of  HIV
acquisition  [51,52].  In  contrast,  although  chronic  HSV-2
infection was also associated with increased HIV-1 acquisition,
the increases were only 2-3 fold [49]. Interestingly, the STEP
trial,  in  which  the  efficacy  of  adenovirus  5  (Ad5)  vectors
encoding HIV gag, pol and nef was tested in human volunteers
[55], vaccine recipients with pre-existing HSV-2 infection had a
3-fold higher risk of HIV-1 acquisition compared to individuals
that  were  seronegative  for  HSV-2;  this  increased  risk  was
noted after adjustments for other risk factors, such as Ad5 titers
and circumcision [56]. Though a clear mechanism accounting
for increased susceptibility to infection remains to be identified,
immunization  with  select  Ad5  vectors  induced  significantly
greater median percentages of activated CCR5 + CD4+ T cells,
suggesting  that  these  cells  may  have  migrated  to  mucosal
sites, thereby increasing the number of target cells available for
HIV infection and enhancing HIV acquisition [57]. In a primate
model of HSV-2/SHIV, upregulation of several of chemokines
and cytokines was described [50]. Acute parasite infection of
RMs  also  significantly  increased  host  susceptibility  to  SHIV
acquisition,  as  our  previous  studies  demonstrated  [53,54].
During acute Schistosoma mansoni infection, the SHIV dose
required to achieve systemic infection after mucosal exposure
was  17-fold  lower  in  parasitized  RMs  compared  to  their
parasite-free counterparts [53,54]. We have noted upregulation
of  several  cytokines  during  acute  infection  with  parasites
[53,54].  The  increased  susceptibility  to  SHIV  acquisition  was
linked to mucosal as opposed to intravenous SHIV challenges
[54].
Our  findings  regarding  live-attenuated  Rev-Ind  Nef¯SIV  as
well  as  examples  from  the  literature  demonstrate  that
inflammation or immune activation at acute stages of infection,
be it with a live-attenuated vaccine strain, HSV-2, or parasites
increase  host  susceptibility  to  de  novo  HIV/SHIV  infection.
Thus, our data highlight the need to consider enhancement of
lentiviral acquisition during acute-stage infection with infectious
agents-cum vaccine candidates. For vaccine trials, live-vector
vaccination may require special warnings to vaccine recipients
regarding increased risks of HIV acquisition during the acute
phase vaccine vector replication.
Materials and Methods
Animals
Indian  RMs  were  housed  at  the  Yerkes  National  Primate
Research Center (YNPRC, Emory University, Atlanta, GA) and
handled  according  to  the  National  Institutes  of  Health
guidelines on the care and use of laboratory animals. Animal
experiments  were  carried  out  in  strict  accordance  with  the
recommendations  in  the  Guide  for  the  Care  and  Use  of
Laboratory Animals of the U.S. Public Health Services/National
Institutes  of  Health,  as  well  as  according  to  the
recommendations in the Weatherall report on ‘‘The Use of Non-
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images/project/nhpdownl.pdf).  The  protocol  was  approved  by
the Committee on the Ethics of Animal Experiments of Emory
University  (IACUC  ID:  YER-256-2008Y;  Emory  University
Animal  Welfare  Assurance  Number  A3180-01).  The  animals
were  housed  indoors  with  a  12  hour  light/dark  cycle,  in
individual cages but in visual and auditory contact with other
RMs, were fed monkey chow (Purina) ad libitum supplemented
daily with fresh fruit. Standard enrichment was provided by the
YNPRC  enrichment  staff  including  perches,  rubber  toys  and
varied treats such as peanuts and cereals. Blood was collected
under ketamine or Telazol anesthesia from the femoral vein.
Animals were closely monitored and observed for development
of disease at least twice daily. Animals determined to be under
stress  or  in  discomfort,  were  administered  appropriate
anesthetics  and/or  analgesics  as  directed  by  the  clinical
veterinary staff. Monkeys showing signs of disease or distress
or reaches IACUC endpoints, such as pain or stress that could
not  be  alleviated  using  standard  analgesics  and/or
chemotherapy were humanely euthanized with an intravenous
overdose of pentobarbital sodium according to the guidelines of
the  American  Veterinary  Medical  Association.  Distribution  of
RMs  into  the  various  groups  is  illustrated  in  Figure  1;
Determination of the major histocompatibility complex (MHC) or
Tripartite-motif 5 alpha (TRIM5α) genotyping were done after
the initiation of the study given the fact that such tools were not
available at the study onset.
Virus stocks
Virus  stocks  were  generated  in  peripheral  blood
mononuclear cells (PBMC) collected from healthy, pathogen-
free RMs and were titrated in vitro using CEMx174-GFP cells
[58]. Rev-Ind Nef¯SIV was generated in our laboratories [25]
and  SIVsmE660  was  obtained  from  the  AIDS  Research  &
Reference  Reagents  Program  (ARRRP),  National  Institute  of
Allergy and Infectious Diseases (NIAID), National Institutes of
Health (NIH), Bethesda, MD, USA. Immunizations with Rev-Ind
Nef¯SIV were given by the i.v. route.
Mucosal SIV challenges
Ketamine-anesthetized  RMs  received  either  low-dose  or
high-dose i.r. inoculations of SIVsmE660 in a total volume of
one ml through a gastric feeding tube, which was, inserted 5
cm  into  the  rectum  with  the  aid  of  a  lubricant.  Virus
administration  (300  50%  tissue  culture  infectious  doses
(TCID50)  for  each  low  and  990  TCID50  for  the  high-dose
challenges)  was  followed  by  two  ml  of  supplement-free
RPMI-1640  medium  and  one  ml  of  air.  The  animals’  pelvis
were left elevated for 15 min before the RMs were returned to
their cages.
Plasma vRNA levels
RNA  was  isolated  using  the  QiaAmp  Viral  RNA  Mini-Kit
(Qiagen, Valencia, CA), and vRNA levels were measured by
quantitative  RT-PCR;  the  assay  sensitivity  was  50  vRNA
copies/ml [32,33].
Differential PCR to distinguish between Rev-Ind
Nef¯SIV and SIVsmE660
We  used  differential  PCR  to  detect  the  vaccine  (Rev-Ind
Nef¯SIV)  and  challenge  (SIVsmE660)  viruses.  SIVmac251-
specific primers and probes developed by Cline et al. [33] were
used  to  detect  vRNA  from  both  Rev-Ind  Nef¯SIV  (vaccine
virus) and SIVsmE660 (challenge virus). Differentiation of the
Rev-Ind  Nef¯SIV  vaccine  virus  from  the  challenge  virus
SIVsmE660  in  the  same  vRNA  sample  was  performed  with
primers  and  probes  specific  for  SIVmac239  developed  by
Hofmann-Lehmann et al. [32].
The  differences  between  these  two  assays  reflect  vRNA
loads of SIVsmE660 superinfection.
ELISPOT assays
PBMC  were  tested  for  virus-specific  responses  using
overlapping  Gag  peptide  pools  of  SIVmac239  (ARRRP)  as
described previously [27,59]. For long-term ELISPOT assays,
cells were cultured at a final concentration of 5 × 106 cells per
ml in 24-well plates for 10 days with SIVmac239 overlapping
Gag peptide pools at a final concentration of 2 µg/ml of each
peptide. Interleukin-2 (IL-2) was added to the cultures every 3
days at a final concentration of 10 U/ml.
MHC class I and TRIM5 α typing of macaques
All RMs were typed for MHC and TRIM5α after completion of
the study since genotyping was not routinely performed at the
time  of  initiation  of  the  current  study.  However,  it  has  since
been reported that select MHC class I alleles are associated
with  delayed  SIV  disease  progression  [60,61]  and  therefore,
typing  for  Mamu-A*001,  B*008  and  B*017  (Table  1)  was
performed to evaluate the distribution of these alleles into the
various  groups.  TRIM5α  genotypes  of  RMs  challenged  with
SIVsmE660 were determined as published [38]. In brief, DNA
was isolated from cryopreserved PBMC and genotyping was
performed at the Genetics Core of the New England Primate
Research Center.
PBMC and rectal biopsy collections
For  microarray  analysis,  blood  was  collected  in  sodium
citrate CPT tubes and centrifuged immediately according to the
manufacturer’s  instructions  to  separate  PBMC  and  plasma;
PBMC were stored in RNAlater solution (Ambion, Austin, TX)
at  -80°C.  Similarly,  rectal  pinch  biopsies  were  collected  2
weeks before and after the administration of Rev-Ind Nef¯SIV.
Rectal pinch biopsies were collected and immediately placed
into  RNAlater  solution  and  stored  -80°C  until  further
processing. We allowed 2 weeks for the rectal tissues to heal
before i.v. inoculation with Rev-Ind Nef¯SIV, the live attenuated
vaccine strain.
RNA extraction and microarray analysis
Total  RNA  from  RMs  PBMC  and  rectal  biopsies  was
extracted  using  RNAeasy  extraction  kits  (Qiagen,  Valencia,
CA). cDNA labeling, hybridization, staining and scanning were
performed  according  to  the  manufacturer’s  instructions
(Affymetrix, Santa Clara, CA).
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Array  quality  was  assessed  using  the  R/Bioconductor
package  [62].  Affymetrix  CEL  files  were  processed  and
normalized  using  the  robust  multiarray  average  (RMA)
algorithm  [63].  Principal  component  analysis  (PCA)  was
performed  on  the  normalized  expression  values  to  identify
phenotypically  similar  groups  by  visualizing  the  top  three
principal  components.  To  identify  genes  correlating  with  the
phenotypic groups, the data were fitted to a linear model using
the  limma  package  [64]  and  tested  for  differential  gene
expression. Results were adjusted for multiple testing using the
Benjamini  and  Hochberg  (BH)  method  [65],  and  significance
was determined using a false-discovery-rate cutoff of <5% and
a log fold-change cutoff of >1. Expression values of significant
probe sets were loaded into the MultiExperiment Viewer (MeV)
[66] and analyzed using average-linkage hierarchical clustering
with  a  Pearson  correlation  coefficient  distance  metric.  Gene
interaction network analysis and visualization were performed
on significant probe sets using the Ingenuity pathway analysis
(IPA)  software  package.  Microarray  data  was  deposited  into
the gene expression omnibus database (GSE49663).
Statistical analyses
The  log-rank  test  was  used  to  compare  the  time-to-peak
viremia  distributions  between  the  groups.  The  Wilcoxon-rank
sum test was used to compare peak viremia between groups.
The Montel-cox test was used to compare difference between
TRIM5α and viral acquisition. All P-values reported are based
on two-sided tests.
Supporting Information
Figure S1.  Analysis of CD4 T cell subsets in Group 7 (n=3)
animals, inoculated with Rev-Ind Nef¯SIV. Data shown are
comparison  of  samples  collected  before  and  2  weeks  post-
infection A) Absolute CD4+ T cells B) CD4+ CD45RA-CCR5+ C)
CD4+  CD45RA-CCR7+  and  D)  Central  Memory  Cells  (CD4+
CD28+ CD95+).
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